Creative Planning
NBIX icon

Creative Planning’s Neurocrine Biosciences NBIX Stock Holding History

Creative Planning’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-100
Closed -$1K – 2226
2020
Q2 		$1K Buy
+100
New +$11.1K ﹤0.01% 1996

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Creative Planning's NBIX Position: Q1 2026 in Review

Creative Planning increased its Neurocrine Biosciences (NBIX) stake by 28% in Q1 2026, buying an estimated $2.01M and bringing the position to 68,387 shares worth $9.01M. The position accounts for 0.01% of the portfolio, ranked #758.

Creative Planning first reported a position in NBIX in Q2 2013 and has held it in 49 quarters since. 694 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.

  • Creative Planning held 68,387 shares of Neurocrine Biosciences worth $9.01M as of Q1 2026.
  • Creative Planning bought 15,121 Neurocrine Biosciences shares in Q1 2026, an estimated $2.01M.
  • Neurocrine Biosciences made up 0.01% of Creative Planning's portfolio in Q1 2026, its #758 holding.
  • Creative Planning first reported a position in Neurocrine Biosciences in Q2 2013 and has held it in 49 quarters since.
  • 694 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.

Based on Creative Planning's 13F filing for Q1 2026, filed 12 May 2026.